Crossmark

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

Published Online: 2023-03-02

Published Print: 2023-03

Authors

Shafer, Danielle

Kagan, Amanda B.

Rudek, Michelle A.

Kmieciak, Maciej

Tombes, Mary Beth

Shrader, Ellen

Bandyopadhyay, Dipankar

Hudson, Daniel

Sankala, Heidi

Weir, Caryn

Lancet, Jeffrey E.

Grant, Steven https://orcid.org/0000-0003-4452-9320
Funding

Funding for this research was provided by:

National Institutes of Health (UH2TR001373, P30CA006973, UL1TR003098, S10OD020091, Massey CCSG P30 CA016059)

National Institutes of Health Experimental Therapeutics Clinical Trials Network (UM1CA186644, U24CA247648)

National Institutes of Health Clinical Pharmacology Training Grant (T32GM066691)

National Center for Advancing Translational Sciences (UL1TR003098)
License Information

Text and Data Mining valid from 2023-03-01

Version of Record valid from 2023-03-01
More Information

Article History

Received: 28 November 2022

Accepted: 8 February 2023

First Online: 2 March 2023

Declarations

:

: No potential conflicts of interest were disclosed by any of the authors.

Document is current